Studies of the mode of action of antitumour triazenes and triazines-III. Metabolism studies on hexamethylmelamine.
These is good evidence that the antitumour agent hexamethylmelamine (HMM) undergoes oxidative metabolic activation which might occur in the liver and/or extrahepatically. The hepatic microsomal N-methylmelamine metabolizing enzymes were investigated in mice and exhibited different affinities for different melamine derivatives. The apparent Km values are 0.09 mM for HMM, 0.23 mM for pentamethylmelamine, 0.91 mM for 2,2,4,6-tetramethylmelamine and 1.7 mM for trimethylmelamine. HMM inhibited its own metabolism in vitro at substrate concentrations greater than 0.05 mM. Its hepatic microsomal N-demethylation rate was reduced when the mice were pretreated with the hepatic glutathione depleting agent methyliodide. Injection of hexaethylmelamine, a derivative of HMM without antineoplastic properties against the M5076 sarcoma in mice, lead to plasma concentrations of drug and metabolite pentaethylmelamine which were only a fraction of the drug and metabolite levels achieved after a similar dose of HMM.
D006585:Altretamine / Q000378:metabolism* / Q000494:pharmacology; D000818:Animals; D001711:Biotransformation; D003640:Dealkylation; D005260:Female; D007700:Kinetics; D008099:Liver / Q000378:metabolism; D051379:Mice; D008815:Mice, Inbred Strains; D013329:Structure-Activity Relationship; D014227:Triazines / Q000378:metabolism*
D014227:Triazines; D006585:Altretamine